CYP3A4/P-glycoprotein inhibitors related colchicine toxicity mimicking septic shock

被引:0
|
作者
Ngeyvijit, Jinjuta [1 ]
Nuansuwan, Sopita [2 ]
Phoophiboon, Vorakamol [3 ,4 ]
机构
[1] Chaophraya Abhaibhubejhr Hosp, Dept Med, Div Pulm & Crit Care Med, Prachin Buri, Thailand
[2] Chaophraya Abhaibhubejhr Hosp, Dept Med, Prachin Buri, Thailand
[3] Chulalongkorn Univ, Fac Med, Dept Med, Div Crit Care Med, Bangkok, Thailand
[4] Univ Toronto, St Michaels Hosp, Div Crit Care Med, Unity Hlth Toronto, Toronto, ON, Canada
关键词
Drug interactions; Adult intensive care; Toxicology; AMERICAN-COLLEGE; INTOXICATION; MANAGEMENT; CLARITHROMYCIN; OVERDOSE; RECOMMENDATIONS; GUIDELINE; DRUGS;
D O I
10.1136/bcr-2023-257186
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Colchicine toxicity is uncommon when patients receive a therapeutic dose regularly. However, inadvertent drug interactions can result in unpredicted adverse outcomes. The toxicity of colchicine can manifest in various ways, ranging from mild and non-specific symptoms to severe form known as multiple organ dysfunction syndrome. This case highlights (1) the diagnostic challenge that arises when distinguishing between the severe manifestation of colchicine toxicity and septic shock and (2) concomitant prescription of colchicine with potent CYP3A4 and P-glycoprotein inhibitors (ie, clarithromycin) can lead to colchicine toxicity despite normal renal and hepatic clearance. Unfortunately, specific tests of colchicine toxicity were not routinely available. A high index of clinical suspicion and recognition of drug interactions with their common presentations are crucial for making diagnosis and management. Failure to recognise drug toxicity can result in poor outcomes.
引用
收藏
页数:5
相关论文
共 50 条
  • [31] Effects of P-glycoprotein (P-GP) inhibitors on CYP3A.
    Wandel, C
    Kim, RB
    Kajiji, S
    Guengerich, FP
    Wood, AJJ
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1998, 63 (02) : 206 - 206
  • [32] Drug-drug interactions involving CYP3A4 and p-glycoprotein in hospitalized elderly patients
    Gallo, Paolo
    De Vincentis, Antonio
    Pedone, Claudio
    Nobili, Alessandro
    Tettamanti, Mauro
    Gentilucci, Umberto Vespasiani
    Picardi, Antonio
    Mannucci, Pier Mannuccio
    Incalzi, Raffaele Antonelli
    Prisco, Domenico
    Silvestri, Elena
    Emmi, Giacomo
    Bettiol, Alessandra
    Caterina, Cenci
    Biolo, Gianni
    Zanetti, Michela
    Guadagni, Martina
    Zaccari, Michele
    Chiuch, Massimiliano
    Vanoli, Massimo
    Grignani, Giulia
    Pulixi, Edoardo Alessandro
    Bernardi, Mauro
    Bassi, Silvia Li
    Santi, Luca
    Zaccherini, Giacomo
    Lupattelli, Graziana
    Mannarino, Elmo
    Bianconi, Vanessa
    Paciullo, Francesco
    Alcidi, Riccardo
    Nuti, Ranuccio
    Valenti, Roberto
    Ruvio, Martina
    Cappelli, Silvia
    Palazzuoli, Alberto
    Girelli, Domenico
    Busti, Fabiana
    Marchi, Giacomo
    Barbagallo, Mario
    Dominguez, Ligia
    Cocita, Floriana
    Beneduce, Vincenza
    Plances, Lidia
    Corrao, Salvatore
    Natoli, Giuseppe
    Mularo, Salvatore
    Raspanti, Massimo
    Cavallaro, Federica
    Zoli, Marco
    EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2019, 65 : 51 - 57
  • [33] Effects of Fluvastatin on the Pharmacokinetics of Repaglinide: Possible Role of CYP3A4 and P-glycoprotein Inhibition by Fluvastatin
    Lee, Chong-Ki
    Choi, Jun-Shik
    Bang, Joon Seok
    KOREAN JOURNAL OF PHYSIOLOGY & PHARMACOLOGY, 2013, 17 (03): : 245 - 251
  • [34] Short term effect of medications on CYP3A4 and P-glycoprotein expression in human intestinal mucosa
    Wille, RT
    Lown, KS
    Huszczo, UR
    SchmiedlinRen, P
    Watkins, PB
    GASTROENTEROLOGY, 1997, 112 (04) : A419 - A419
  • [35] Discovery and Characterization of Potent Dual P-Glycoprotein and CYP3A4 Inhibitors: Design, Synthesis, Cryo-EM Analysis, and Biological Evaluations
    Urgaonkar, Sameer
    Nosol, Kamil
    Said, Ahmed M.
    Nasief, Nader N.
    Bu, Yahao
    Locher, Kaspar P.
    Lau, Johnson Y. N.
    Smolinski, Michael P.
    JOURNAL OF MEDICINAL CHEMISTRY, 2022, 65 (01) : 191 - 216
  • [36] Design, synthesis, molecular modeling, in vitro and in vivo biological evaluation of potent anthranilamide derivatives as dual P-glycoprotein and CYP3A4 inhibitors
    Said, Ahmed M.
    Mansour, Yara E.
    Soliman, Radwa R.
    Islam, Ridwan
    Fatahala, Samar S.
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2024, 273
  • [37] Mechanistic Insight from In Silico Pharmacokinetic Experiments: Roles of P-glycoprotein, Cyp3A4 Enzymes, and Microenvironments
    Lam, Tai Ning
    Hunt, C. Anthony
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2010, 332 (02): : 398 - 412
  • [38] COMPUTATIONAL MODELS TO EXPLAIN THE RELATIONSHIP AMONG P-GLYCOPROTEIN, CYP3A4 AND BIOAVAILABILITY FROM MOLECULAR STRUCTURE
    Angel Cabrera-Perez, Miguel
    Castillo-Gonzalez, Daimel
    Gonzalez-Alvarez, Isabel
    Bermejo-Sanz, Marival
    DRUGS OF THE FUTURE, 2009, 34 : 209 - 209
  • [39] Prediction of Nonlinear Intestinal Absorption of CYP3A4 and P-Glycoprotein Substrates from their In Vitro Km Values
    Tatsuhiko Tachibana
    Motohiro Kato
    Yuichi Sugiyama
    Pharmaceutical Research, 2012, 29 : 651 - 668
  • [40] Prediction of Nonlinear Intestinal Absorption of CYP3A4 and P-Glycoprotein Substrates from their In Vitro Km Values
    Tachibana, Tatsuhiko
    Kato, Motohiro
    Sugiyama, Yuichi
    PHARMACEUTICAL RESEARCH, 2012, 29 (03) : 651 - 668